- Professor Eisuke Fukuma, who has performed over 600
ProSense breast cancer cryoablation procedures, led a cryoablation
symposium with ProSense
- IceCure joined its exclusive regional distributor,
Terumo, to exhibit the ProSense System to physicians seeking
minimally invasive alternatives to
lumpectomy
CAESAREA, Israel, Aug. 21,
2023 /PRNewswire/ -- IceCure Medical LTD. (Nasdaq:
ICCM) ("IceCure" or the "Company"), developer of the ProSense®
System, a minimally-invasive cryoablation technology that destroys
tumors by freezing as an alternative to surgical tumor removal,
recently participated in the 16th Thai Breast Symposium
in Bangkok, Thailand, which was
hosted by the Thai Breast Surgeons Society. IceCure
representatives, including VP of Business Development & Global
Marketing, Tlalit Bussi Tel-Tzure, participated at Terumo
Corporation's (Tokyo: 4543;US OTC:
TRUMY) booth. Terumo is the Company's exclusive distributor of the
ProSense System in Japan and
Thailand.
A cryoablation symposium, "Cryoablation Emerging as Effective
Treatment for Breast Cancer", was led by Professor Eisuke Fukuma, Director of the Breast Center at
Kameda Medical Center, Japan.
Professor Fukuma commented, "I've performed over 600 breast
tumor procedures with ProSense with excellent results. Patients
have minimal pain, no change to the volume or the shape of the
breast, and they can quickly resume their normal activities the day
following the procedure. Because of this, many women come to my
facility and seek out cryoablation. I am pleased to be here at the
conference to inform and educate other doctors on how to use
ProSense to benefit their patients."
Israel's Ambassador to
Thailand, Orna Sagiv, added, "IceCure's breakthrough
technology marks a new era in women's health treatment. This
innovative solution to treat benign and malignant tumors allows for
a safe and effective procedure without the trauma, pain, and
scarring which has been inevitable until now. This technology
represents a new hope for patients and their families facing a
cancer diagnosis. The partnership between IceCure, an Israeli
company, and Terumo Thailand is another manifestation of the
Thai-Israeli potential for collaboration that will improve the
lives of both Thais and Israelis. The Embassy of Israel supports this unique partnership and
hopes it will help save many lives."
"The growing amount of data on ProSense's efficacy in treating
tumors of the breast, lung, and kidney supports our sales momentum
in Thailand since ProSense was
approved to treat these cancers," stated Terumo Thailand's Managing
Director, Panapon Chantakulchai. "Highlighting ProSense at the Thai
Breast Society Symposium is very timely as the global medical
community recognizes the benefits of this cost-efficient,
non-invasive and effective option."
IceCure's Tlalit Bussi Tel-Tzure, commented, "We had very strong
interest in ProSense both at the Terumo booth and at Professor
Fukuma's talk. The awareness around cryoablation as a minimally
invasive method to treat early-stage breast cancer continues to
gain momentum and ProSense is extremely well positioned as the
system of choice for breast surgeons. Terumo has been a great
partner for us in Thailand where
we expect to see growing sales momentum."
About IceCure Medical
IceCure Medical (Nasdaq: ICCM)
develops and markets ProSense®, an advanced liquid-nitrogen-based
cryoablation therapy for the treatment of tumors (benign and
cancerous) by freezing, with the primary focus areas being breast,
kidney, bone and lung cancer. Its minimally invasive technology is
a safe and effective alternative to hospital surgical tumor removal
that is easily performed in a relatively short procedure. The
system is marketed and sold worldwide for the indications cleared
and approved to date including in the U.S., Europe, and China.
Forward looking Statements
This press release contains forward looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other federal and
Israeli securities laws. Words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates" and similar
expressions or variations of such words are intended to identify
forward looking statements. For example, IceCure is using forward
looking statement in this press release when it discusses that
IceCure's breakthrough technology marks a new era in women's health
treatment, that this technology represents a new hope for patients
who face a cancer diagnosis, that the partnership between IceCure
and Terumo Thailand will improve the lives of Thais and Israelis,
that the ProSense System is well positioned as the system of choice
for breast surgeons and that IceCure expects to see growing sales
momentum in Thailand. Because such
statements deal with future events and are based on IceCure's
current expectations, they are subject to various risks and
uncertainties and actual results, performance, or achievements of
IceCure could differ materially from those described in or implied
by the statements in this press release. The forward looking
statements contained or implied in this press release are subject
to other risks and uncertainties, many of which are beyond the
control of the Company, including those set forth in the Risk
Factors section of the Company's Annual Report on Form 20-F for the
year ended December 31, 2022 filed
with the SEC on March 29, 2023, and
other documents filed with or furnished to the SEC which are
available on the SEC's website, www.sec.gov. The Company undertakes
no obligation to update these statements for revisions or changes
after the date of this release, except as required by law.
IR Contact:
Michael Polyviou
Phone: 732-232-6914
Email: mpolyviou@evcgroup.com
Todd Kerhli
Phone: 310-625-4462
Email: tkehrli@evcgroup.com
Logo -
https://mma.prnewswire.com/media/1941429/IceCure_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/icecure-medical-continues-to-experience-growing-global-interest-in-prosense-featured-at-the-16th-thai-breast-symposium-301905403.html
SOURCE IceCure Medical